We use essential cookies (authentication, your saved goals/stack) by default. With your permission we'll also enable privacy-respecting analytics (Vercel Web Analytics, anonymous load-time metrics) and error-replay diagnostics (Sentry — DOM snapshots only when an error fires) so we can fix bugs faster. Learn more about cookies
Research peptide — not a dietary supplement
Sermorelin is a research compound, not a regulated dietary supplement. It is typically administered by injection and sold “for research use only.” The evidence below is largely preclinical (animal and in-vitro) or early-stage, so no evidence score is assigned. This page is provided for transparency and education — it is not a recommendation to use. Consult a qualified healthcare provider, and be aware that purity, dosing, and legal status vary by jurisdiction.
What the evidence says
Most Sermorelin studies are mechanism or observational rather than RCTs that measure a clinical effect — keep findings provisional.
Most evidence is from mixed-quality randomised trials published 1986–2005 with a typical study size of 19 participants.
Based on 10 studies · 6 RCTs · 257 total participants
Confidence
ModerateBy outcome
Sermorelin has an evidence score of 3.5/10 — emerging evidence based on 10 indexed studies. An injectable analogue of growth-hormone-releasing hormone (the first 29 amino acids of GHRH) that stimulates the pituitary to release growth hormone. Honest appraisal: this WAS an FDA-approved prescription drug (Geref) with real human trials — for diagnosing GH deficiency and treating GH-deficient children — but it was discontinued commercially. Its current marketing as a compounded 'anti-aging' peptide is off-label and is NOT what those trials validated. Representative study: PMID 8329826.
The commonly studied dose of Sermorelin is Prescription-only; historic regimens used ~30 µg/kg/day subcutaneously for pediatric GH deficiency. No validated dietary-supplement dose exists.. Individual needs vary — start at the lower end of the range and adjust based on how you respond.
PT-141
Mostly mechanism / observationalA melanocortin-receptor (MC4R) agonist peptide for low sexual desire. Important honest framing: unlike most 'research peptides', bremelanotide is an FDA-APPROVED prescription drug — Vyleesi, approved 2019 — for acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women, self-injected subcutaneously on-demand. It has real phase-3 RCTs (the RECONNECT program). The catch: the approved-trial benefit was statistically significant but small (a fraction of a point on desire scales), nausea is very common, and it transiently raises blood pressure. Grey-market 'PT-141' vials sold online are NOT the approved drug and are unregulated.
Last reviewed June 2026 · evidence from 10 studies · how we score
This information is for educational purposes only. It is not a substitute for professional medical advice. Always consult a qualified healthcare provider before starting, stopping, or changing any supplement or medication.
Sermorelin (GHRH(1-29))
An injectable analogue of growth-hormone-releasing hormone (the first 29 amino acids of GHRH) that stimulates the pituitary to release growth hormone. Honest appraisal: this WAS an FDA-approved prescription drug (Geref) with real human trials — for diagnosing GH deficiency and treating GH-deficient children — but it was discontinued commercially. Its current marketing as a compounded 'anti-aging' peptide is off-label and is NOT what those trials validated.
Emerging because real trials validate only its diagnostic use and pediatric GH-deficiency treatment, while the marketed 'anti-aging' use rests on small aging trials that measured GH/IGF-1, not clinical benefit.
Sermorelin is a synthetic 29-amino-acid peptide corresponding to the biologically active N-terminal fragment of human growth-hormone-releasing hormone, GHRH(1-29)-NH2.
It binds the GHRH receptor on pituitary somatotrophs and stimulates the synthesis and pulsatile release of endogenous growth hormone (GH), which in turn raises IGF-1.
Because it works upstream of the pituitary and preserves the body's own feedback loops, it produces a more physiologic GH pulse than injected recombinant GH.
Sermorelin has a genuine clinical pedigree: it was marketed as the FDA-approved prescription drug Geref, used both as a diagnostic agent (the GHRH stimulation test for GH deficiency) and as a treatment to accelerate growth in children with GH deficiency of hypothalamic/pituitary origin.
The pediatric evidence is real — including a multicentre study and randomized comparisons against recombinant GH — and the diagnostic use is well established.
Importantly, controlled pediatric trials found that conventional GH replacement generally out-performed GHRH for growth, and Geref was subsequently discontinued commercially.
The compound has also been studied in healthy aging adults: small randomized placebo-controlled trials showed it can raise nocturnal GH pulsatility and IGF-1, but did not establish the body-composition, vitality, or anti-aging clinical benefits now claimed in its compounded-pharmacy marketing.
So the honest picture is two-tiered: legitimate, trial-backed evidence for diagnosis and pediatric GH-deficiency (its original approved indications), and an unproven, off-label 'anti-aging' use that the existing human trials do not support.
It is a prescription drug, not a dietary supplement, is given by subcutaneous injection, affects the GH/IGF-1 axis, and is banned in sport by WADA.
GHRH(1-29) is the active fragment of growth-hormone-releasing hormone; it binds the GHRH receptor on pituitary somatotrophs to trigger GH synthesis and release.
By acting upstream of the pituitary, it stimulates the body's own pulsatile GH secretion (preserving feedback regulation), which raises circulating IGF-1.
How Sermorelin works — from molecular targets to health outcomes. Click an edge to see supporting research.This visualization is in beta — pathways are being refined and expanded.
Tap node to isolate • Pinch to zoom • Tap edge for research
Prescription-only; historic regimens used ~30 µg/kg/day subcutaneously for pediatric GH deficiency. No validated dietary-supplement dose exists.
Can be taken without food
| Form | Type |
|---|---|
| 💊Sermorelin acetate (subcutaneous injection) | Recommended |
A prescription peptide drug, not a dietary supplement. The FDA-approved branded product (Geref) has been discontinued; today it is supplied through compounding pharmacies.
Minimum: 4 weeks
Optimal: 16 weeks
Cycling: Not required
Note: Trials dosed at night to align with the physiologic nocturnal GH pulse. This reflects research/clinical protocols, not validated supplement timing.
Dose-response data unavailable. The current published research for Sermorelin does not provide sufficient dose-specific outcome data to generate reliable dose-response curves.
Refer to the Dosage & Timing section above for recommended dose ranges based on available evidence.
Reliably evokes an acute rise in serum GH after injection — the basis for both the GHRH stimulation (diagnostic) test and the growth-promoting use.
Daily subcutaneous GHRH(1-29) increased height velocity in GH-deficient children in trials — though recombinant GH generally worked better.
Small aging trials raised GH/IGF-1 but did not validate the body-composition or vitality claims used in compounded 'anti-aging' marketing.
Local injection-site reactions are the most common adverse effect; impaired glucose tolerance was seen with repeated GHRH dosing in the elderly.
Only under specialist endocrinology care for diagnosed GH deficiency — not for general use.
Trials raised GH/IGF-1 but showed glucose-tolerance impairment with repeated dosing; clinical anti-aging benefit is unproven.
Avoid — stimulating the GH/IGF-1 axis is a theoretical proliferation risk.
Avoid — not established as safe.
Prohibited by WADA at all times (GH-releasing agent) — using it risks an anti-doping violation.
Glucocorticoids can blunt the GH response to GHRH, reducing efficacy.
GH-axis stimulation can impair glucose tolerance (observed with repeated GHRH dosing in elderly subjects); may affect glycemic control.
Tip: Rotate injection sites; reactions in trials were mild and transient
Tip: Monitor glucose, especially with repeated dosing and in older adults
Tip: Usually transient
The best time to take Sermorelin is before bed. It can be taken on an empty stomach. Pediatric GH-deficiency trials dosed once daily at bedtime (or in divided nocturnal doses) to mimic the physiologic overnight GH pulse.
Sermorelin should be used with caution — talk to a healthcare provider before taking it. The most commonly reported side effects are injection-site reaction (pain, redness, swelling), impaired glucose tolerance, headache / flushing. Use caution if any of these apply to you: Pregnancy/breastfeeding; Active or suspected malignancy (GH/IGF-1 axis stimulation); Use without medical supervision.
Gonadorelin
Mostly mechanism / observationalA synthetic copy of gonadotropin-releasing hormone (GnRH), the hypothalamic decapeptide that drives the pituitary to release LH and FSH. Honest appraisal: it has genuine, trial-backed roles as a diagnostic agent (the GnRH/gonadorelin stimulation test) and — delivered in pulses by an infusion pump — for inducing ovulation in hypothalamic amenorrhea and spermatogenesis in men with congenital hypogonadotropic hypogonadism. Its now-trendy use in men's TRT clinics (compounded, to 'maintain testosterone/fertility' alongside testosterone, often replacing hCG) is largely off-label and has NOT been validated in controlled trials for that purpose.
Agents that alter somatostatin tone or thyroid status can modulate the GH response to GHRH.